Citations

Clear

1575 citation(s) found for "Im, Gene".

Human Glucocorticoid Receptor α Gene (NR3C1) Pharmacogenomics: Gene Resequencing and Functional Genomics
Niu, Nifang, Kalari, Krishna R. , Moon, Irene, Pelleymounter, Linda L., Eckloff, Bruce W., Wieben, Eric D. , Schaid, Daniel J. , Wang, Liewei , Manickam, Venkatraman , Kalari, Krishna R

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 13, 2009 | Volume: 94 | Issue: 8 | Pages: 3072-3084

10.1210/jc.2008-2109 | PMID 19435830 Get It

Fine Mapping of Chromosome 6q23-25 Region in Familial Lung Cancer Families Reveals RGS17 as a Likely Candidate Gene
You, Ming , Wang, Daolong, Liu, Pengyuan , Vikis, Haris G., James, Michael A. , Wang, Yian , Jia, Dongmei , Wen, Weidong, Sun, Zhifu , Pinney, Susan M. , Zheng, Wei , Shu, Xiao‐Ou , Long, Jirong , Gao, Yu-Tang, Xiang, Yong-Bing , Chow, Wong‐Ho , Rothman, Nat, Petersen, Gloria M. , Cunningham, Julie M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Girard, Luc , Gazdar, Adi, Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Coons, Teresa, Lee, Juwon , Kupert, Elena, Seminara, Daniela, Bailey‐Wilson, Joan E. , Anderson, Marshall W., Lü, Yan , Wang, Min , Chen, Qiong , Liu, Yan , Yang, Ping , Andrade, Mariza de , Wu, Yanhong , Minna, John Dorrance , Amos, Christopher I. , Sun, Zhifu , Wilson, Richard K , Shu, Xiao-Ou , Zheng, Wei , Pinney, Susan M

Mayo Clinic

Clinical Cancer Research | April 7, 2009 | Volume: 15 | Issue: 8 | Pages: 2666-2674

10.1158/1078-0432.ccr-08-2335 | PMID 19351763 Get It

Abstract Purpose: We have previously mapped a major susceptibility locus influencing familial lung cancer risk to chromosome 6q23-25. However, the causal gene at this locus remains undetermined. In this study, we further refined this locus to identify a single candidate gene, by fine mapping using microsatellite markers and association studies using high-density single nucleotide polymorphisms (SNP). Experimental Design: Six multigenerational families with five or more affected members were chosen for fine-mapping the 6q linkage region using microsatellite markers. For association mapping, we genotyped 24 6q-linked cases and 72 unrelated noncancer controls from the Genetic Epidemiology of Lung Cancer Consortium resources using the Affymetrix 500K chipset. Significant associations were validated in two independent familial lung cancer populations: 226 familial lung cases and 313 controls from the Genetic Epidemiology of Lung Cancer Consortium, and 154 familial cases and 325 controls from Mayo Clinic. Each familial case was chosen from one high-risk lung cancer family that has three or more affected members. Results: A region-wide scan across 6q23-25 found significant association between lung cancer susceptibility and three single nucleotide polymorphisms in the first intron of the RGS17 gene. This association was further confirmed in two independent familial lung cancer populations. By quantitative real-time PCR analysis of matched tumor and normal human tissues, we found that RGS17 transcript accumulation is highly and consistently increased in sporadic lung cancers. Human lung tumor cell proliferation and tumorigenesis in nude mice are inhibited upon knockdown of RGS17 levels. Conclusion: RGS17 is a major candidate for the familial lung cancer susceptibility locus on chromosome 6q23-25.
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Reiman, Eric M. , Chen, Kewei , Bandy, Daniel, Yu, Meixiang , Lee, Wendy , Ayutyanont, Napatkamon , Keppler, Jennifer, Reeder, Stephanie, Alexander, Gene E. , Klunk, William E. , Mathis, Chester A. , Price, Julie C. , Aizenstein, Howard , DeKosky, Steven T. , Caselli, Richard J. , Liu, Xiaofen , Reeder, Stephanie, Langbaum, Jessica B. S.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 3, 2009 | Volume: 106 | Issue: 16 | Pages: 6820-6825

10.1073/pnas.0900345106 | PMID 19346482 Get It

Fibrillar amyloid-beta (Aβ) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.
Early gene expression changes induced by the bacterial superantigen staphylococcal enterotoxin B and its modulation by a proteasome inhibitor
Rajagopalan, Govindarajan , Tilahun, Ashenafi Y. , Asmann, Yan W. , David, Chella S.

Mayo Clinic

Physiological Genomics | April 1, 2009 | Volume: 37 | Issue: 3 | Pages: 279-293

10.1152/physiolgenomics.90385.2008 | PMID 19336531 Get It

Toxic shock syndrome (TSS) is an acute, serious systemic illness caused by bacterial superantigens. Nonavailability of a suitable animal model until recently has hampered an in-depth understanding of the pathogenesis of TSS. In the current study, we characterized the early molecular events underlying TSS using our HLA-DR3 transgenic mouse model. Gene expression profiling using DNA microarrays identified a rapid and significant upregulation of several pro- as well as anti-inflammatory mediators, many of which have never been previously described in TSS. In vivo administration of staphylococcal enterotoxin B (SEB) led to an increase in the expression of Th0- (IL-2, 240-fold); Th1- (IFN-γ, 360-fold; IL-12, 8-fold); Th2- (IL-4, 53-fold; IL-5, 4-fold) as well as Th17-type cytokines (IL-21, 19-fold; IL-17, 5-fold). The immunoregulatory cytokines (IL-6, 700-fold; IL-10, 18-fold); CC chemokines (such as CCL 2, 11, 3, 24, 17, 12, 7), CXC chemokines (such as CXCL 1, 2, 5, 11, 10, 19); and several proteases (matrix metalloproteinases 13, 8, 3, and 9) were also upregulated. Serum levels of several of these cytokines/chemokines were also significantly elevated. Pathway analyses revealed significant modulation in a variety of biochemical and cellular functions, providing molecular insights into the pathogenesis of TSS. Administration of bortezomib, a clinically approved proteasome inhibitor capable of blocking NF-κB pathway, was able to significantly modulate the expression of a variety of genes induced by SEB. Thus, our study showed that TSS is a complex process and emphasized the potential of use of bortezomib in the therapy of superantigen-induced TSS.
Multicenter Validation of a 1,550-Gene Expression Profile for Identification of Tumor Tissue of Origin
Monzon, Federico A. , Lyons‐Weiler, Maureen A., Buturović, Ljubomir , Rigl, C. Ted, Henner, W. David, Sciulli, Christin, Dumur, Catherine I. , Medeiros, Fabíola, Anderson, Glenda G.

Mayo Clinic

Journal of Clinical Oncology | March 31, 2009 | Volume: 27 | Issue: 15 | Pages: 2503-2508

10.1200/jco.2008.17.9762 | PMID 19332734 Get It

Purpose Malignancies found in unexpected locations or with poorly differentiated morphologies can pose a significant challenge for tissue of origin determination. Current histologic and imaging techniques fail to yield definitive identification of the tissue of origin in a significant number of cases. The aim of this study was to validate a predefined 1,550-gene expression profile for this purpose. Methods Four institutions processed 547 frozen specimens representing 15 tissues of origin using oligonucleotide microarrays. Half of the specimens were metastatic tumors, with the remainder being poorly differentiated and undifferentiated primary cancers chosen to resemble those that present as a clinical challenge. Results In this blinded multicenter validation study the 1,550-gene expression profile was highly informative in tissue determination. The study found overall sensitivity (positive percent agreement with reference diagnosis) of 87.8% (95% CI, 84.7% to 90.4%) and overall specificity (negative percent agreement with reference diagnosis) of 99.4% (95% CI, 98.3% to 99.9%). Performance within the subgroup of metastatic tumors (n = 258) was found to be slightly lower than that of the poorly differentiated and undifferentiated primary tumor subgroup, 84.5% and 90.7%, respectively (P = .04). Differences between individual laboratories were not statistically significant. Conclusion This study represents the first adequately sized, multicenter validation of a gene-expression profile for tissue of origin determination restricted to poorly differentiated and undifferentiated primary cancers and metastatic tumors. These results indicate that this profile should be a valuable addition or alternative to currently available diagnostic methods for the evaluation of uncertain primary cancers.
Molecular evolution of the junctophilin gene family
Garbino, Alejandro , Oort, Ralph J. van, Dixit, Sayali S., Landstrom, Andrew P. , Ackerman, Michael J. , Wehrens, Xander H.T. , Landstrom, Andrew P , Wehrens, Xander H T

Mayo Clinic

Physiological Genomics | March 25, 2009 | Volume: 37 | Issue: 3 | Pages: 175-186

10.1152/physiolgenomics.00017.2009 | PMID 19318539 Get It

Junctophilins (JPHs) are members of a junctional membrane complex protein family important for the physical approximation of plasmalemmal and sarcoplasmic/endoplasmic reticulum membranes. As such, JPHs facilitate signal transduction in excitable cells between plasmalemmal voltage-gated calcium channels and intracellular calcium release channels. To determine the molecular evolution of the JPH gene family, we performed a phylogenetic analysis of over 60 JPH genes from over 40 species and compared conservation across species and different isoforms. We found that JPHs are evolutionary highly conserved, in particular the membrane occupation and recognition nexus motifs found in all species. Our data suggest that an ancestral form of JPH arose at the latest in a common metazoan ancestor and that in vertebrates four isoforms arose, probably following two rounds of whole genome duplications. By combining multiple prediction techniques with sequence alignments, we also postulate the presence of new important functional regions and candidate sites for posttranslational modifications. The increasing number of available sequences yields significant insight into the molecular evolution of JPHs. Our analysis is consistent with the emerging concept that JPHs serve dual important functions in excitable cells: structural assembly of junctional membrane complexes and regulation of intracellular calcium signaling pathways.
Prolonged Transgene Expression with Lentiviral Vectors in the Aqueous Humor Outflow Pathway of Nonhuman Primates
Barraza, Román, Rasmussen, Carol A. , Loewen, Nils A. , Cameron, J. Douglas, Gabelt, B’Ann T., Teo, Wulin , Kaufman, Paul L., Poeschla, Eric M.

Mayo Clinic

Human Gene Therapy | March 17, 2009 | Volume: 20 | Issue: 3 | Pages: 191-200

10.1089/hum.2008.086 | PMID 19301472 Get It

Candidate Gene Analysis Using Imputed Genotypes: Cell Cycle Single-Nucleotide Polymorphisms and Ovarian Cancer Risk
Goode, Ellen L. , Vierkant, Robert A. , Cunningham, Julie M. , Phelan, Catherine M., Anderson, S. Keith , Rider, David N., White, Kristin L., Pankratz, V. Shane , Song, Honglin , Høgdall, Estrid , Kjær, Susanne K. , Whittemore, Alice S. , DiCioccio, Richard A., Ramus, Susan J. , Gayther, Simon A. , Schildkraut, Joellen M. , Pharaoh, Paul, Sellers, Thomas A. , Fridley, Brooke L. , Kjaer, Susanne K , Ramus, Susan J , Vierkant, Robert A , Høgdall, Estrid

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 9, 2009 | Volume: 18 | Issue: 3 | Pages: 935-944

10.1158/1055-9965.epi-08-0860 | PMID 19258477 Get It

Abstract Polymorphisms in genes critical to cell cycle control are outstanding candidates for association with ovarian cancer risk; numerous genes have been interrogated by multiple research groups using differing tagging single-nucleotide polymorphism (SNP) sets. To maximize information gleaned from existing genotype data, we conducted a combined analysis of five independent studies of invasive epithelial ovarian cancer. Up to 2,120 cases and 3,382 controls were genotyped in the course of two collaborations at a variety of SNPs in 11 cell cycle genes (CDKN2C, CDKN1A, CCND3, CCND1, CCND2, CDKN1B, CDK2, CDK4, RB1, CDKN2D, and CCNE1) and one gene region (CDKN2A-CDKN2B). Because of the semi-overlapping nature of the 123 assayed tagging SNPs, we performed multiple imputation based on fastPHASE using data from White non-Hispanic study participants and participants in the international HapMap Consortium and National Institute of Environmental Health Sciences SNPs Program. Logistic regression assuming a log-additive model was done on combined and imputed data. We observed strengthened signals in imputation-based analyses at several SNPs, particularly CDKN2A-CDKN2B rs3731239; CCND1 rs602652, rs3212879, rs649392, and rs3212891; CDK2 rs2069391, rs2069414, and rs17528736; and CCNE1 rs3218036. These results exemplify the utility of imputation in candidate gene studies and lend evidence to a role of cell cycle genes in ovarian cancer etiology, suggest a reduced set of SNPs to target in additional cases and controls. (Cancer Epidemiol Biomarkers Prev 2009;18(3):935–44)
Bladder Cancer–Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia
Rosser, Charles J. , Liu, Li , Villicana, Patrick, McCullers, Molly, Porvasnik, Stacy, Parker, Alexander S. , Goodison, Steve , Sun, Yijun , Young, Paul R.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 10, 2009 | Volume: 18 | Issue: 2 | Pages: 444-453

10.1158/1055-9965.epi-08-1002 | PMID 19190164 Get It

Abstract Bladder cancer is the fifth most commonly diagnosed malignancy in the United States and one of the most prevalent worldwide. It harbors a probability of recurrence of >50%; thus, rigorous, long-term surveillance of patients is advocated. Flexible cystoscopy coupled with voided urine cytology is the primary diagnostic approach, but cystoscopy is an uncomfortable, invasive procedure and the sensitivity of voided urine cytology is poor in all but high-grade tumors. Thus, improvements in noninvasive urinalysis assessment strategies would benefit patients. We applied gene expression microarray analysis to exfoliated urothelia recovered from bladder washes obtained prospectively from 46 patients with subsequently confirmed presence or absence of bladder cancer. Data from microarrays containing 56,000 targets was subjected to a panel of statistical analyses to identify bladder cancer-associated gene signatures. Hierarchical clustering and supervised learning algorithms were used to classify samples on the basis of tumor burden. A differentially expressed geneset of 319 gene probes was associated with the presence of bladder cancer (P < 0.01), and visualization of protein interaction networks revealed vascular endothelial growth factor and angiotensinogen as pivotal factors in tumor cells. Supervised machine learning and a cross-validation approach were used to build a 14-gene molecular classifier that was able to classify patients with and without bladder cancer with an overall accuracy of 76%. Our results show that it is possible to achieve the detection of bladder cancer using molecular signatures present in exfoliated tumor urothelia. Further investigation and validation of the cancer-associated profiles may reveal important biomarkers for the noninvasive detection and surveillance of bladder cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(2):444–53)
Short-Term Rescue of Neonatal Lethality in a Mouse Model of Propionic Acidemia by Gene Therapy
Hofherr, Sean, Senac, Julien S., Chen, Christopher Y. , Palmer, Donna , Ng, Philip , Barry, Michael A. , Barry, Michael A

Mayo Clinic

Human Gene Therapy | January 26, 2009 | Volume: 20 | Issue: 2 | Pages: 169-180

10.1089/hum.2008.158 | PMID 19025475 Get It